Makary Would Have Wide Leeway To Make GLP-1 Compounding Decisions As US FDA Commissioner

 
• By Sarah Karlin-Smith
  
magnifying glass over GLP-1 written on scrap of paper. other paper scraps read "obesity," "semaglutide" "weight loss"
The FDA Commissioner nominee can play an active role in GLP-1 policy despite past conflicts of interest. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA

More from Geography